A confirmed methamphetamine result identifies an analyte in the submitted specimen. A claim that the person deliberately took a second drug adds a source-and-behavior inference. A 2025 Swedish investigation is useful because it examined a pattern that can make that inference difficult: substantial urinary amphetamine with very little methamphetamine.
What did the primary study actually examine?
Helander, Andersson and Villén reviewed 12,062 routine urine confirmation results following positive amphetamine-class screens. Amphetamine was reportable in 10,371 samples; methamphetamine in 259, using a 200 μg/L reporting limit. Among those 259, 69% had methamphetamine below 2% of the amphetamine concentration.
Selected chiral analyses included eight medication-associated urine samples containing d-amphetamine and 2.2–22.9 μg/L d-methamphetamine, representing 0.01–0.06% of amphetamine. One Elvanse capsule preparation and one Attentin tablet preparation had no methamphetamine detected. The authors interpreted these findings as support for trace N-methylation of amphetamine. This was observational laboratory evidence with selected follow-up samples, not a controlled tracer demonstration establishing the pathway in every person. “Not detected” describes the analytical result, rather than an absolute absence at every possible sensitivity.
Why do the denominators and units matter?
The 259 reportable methamphetamine results and the eight selected medication-associated samples answer different questions. The former describes a laboratory testing series; the latter explores an explanatory pattern. Treating eight selected samples as eight randomly sampled medication users would add a sampling assumption that needs its own support.
Likewise, a proportion must identify both numerator and denominator. A methamphetamine-to-amphetamine percentage is different from a percentage of people who took methamphetamine. A small concentration ratio cannot be relabeled as a small probability of separate ingestion without a model connecting those quantities.
For unit checking, 1 μg/L equals 1 ng/mL. Converting the label does not change the concentration or make a low-level finding more substantial. Keep both analytes in matching units before calculating any ratio.
Does this establish an innocent explanation for every low result?
No. The appropriate methodological conclusion is that a proposed explanation must be evaluated against the actual evidence. Demonstrating that an alternative is plausible does not identify which explanation operated in an individual specimen. Conversely, the mere existence of an analytically confirmed peak does not supply the missing evidence about its source.
A defensible assessment should distinguish the laboratory identification, the proposed origin, and the claimed conduct. Each step should state its assumptions and what evidence could distinguish competing explanations. That approach permits a conclusion to remain uncertain when the available measurements cannot resolve it.
What should be reviewed in an actual testing dispute?
Request the quantitative results for both analytes, the reporting and quantification limits, relevant blanks and carryover checks, dilution records, medication information, and any chiral data. These are suggested review steps, not findings that a particular laboratory made an error. If a product explanation is proposed, identify the actual product evidence supporting it rather than treating a drug name as proof about a particular batch.
The study concerns urine source interpretation. It should not be converted into a blood concentration, an exact ingestion time, a dose estimate, or proof of impairment at an earlier event.
Scientific source
Helander A, Andersson A, Villén T. Origin and Interpretation of Low Methamphetamine Levels Found in Amphetamine-Positive Urine Samples: Support for Methylation of Amphetamine as a Minor Metabolic Pathway. Drug Testing and Analysis. 2025;17:2276–2282. Published August 7, 2025. Primary observational laboratory study. DOI: 10.1002/dta.3940. Publisher full text.